1.
Lancet Oncol
; 17(9): e371, 2016 09.
Article
in English
| MEDLINE
| ID: mdl-27599139
Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Immunoconjugates/therapeutic use , Ki-1 Antigen/immunology , Lymphoma/drug therapy , Antineoplastic Agents, Immunological/adverse effects , Brentuximab Vedotin , Disease Progression , Disease-Free Survival , Humans , Immunoconjugates/adverse effects , Lymphoma/immunology , Lymphoma/mortality , Lymphoma/pathology , Treatment Outcome
2.
Nat Rev Cardiol
; 13(10): 574, 2016 10.
Article
in English
| MEDLINE
| ID: mdl-27538816